Assessing Quality of Life in Psoriasis Patients
Author Information
Author(s): Shikiar Richard, Willian Mary Kaye, Okun Martin M, Thompson Christine S, Revicki Dennis A
Primary Institution: United BioSource Corporation
Hypothesis
The study aims to evaluate the validity and responsiveness of three quality of life measures in psoriasis patients.
Conclusion
The study supports the use of the DLQI and SF-36 PCS in assessing treatments for psoriasis, while suggesting the EQ-5D as a general measure for future trials.
Supporting Evidence
- The DLQI was highly correlated with clinical endpoints at both baseline and Week 12.
- The EQ-5D index score showed strong correlations with clinical endpoints.
- The study established the reliability and validity of the DLQI in assessing psoriasis.
Takeaway
This study looked at how well different questionnaires measure the quality of life for people with psoriasis and found that some are better than others.
Methodology
A Phase II, randomized, double-blind, placebo-controlled trial assessed the efficacy and safety of adalimumab in 147 psoriasis patients over 12 weeks.
Potential Biases
The study was conducted with blinded data to minimize bias.
Limitations
The sample size was limited and may not be generalizable to all psoriasis patients.
Participant Demographics
{"mean_age":44.2,"gender_distribution":{"male":67.3,"female":32.7},"race_distribution":{"white":90.5,"black":2.7,"asian":3.4,"other":3.4}}
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website